In this study， we compared the expression of epithelial membrane protein 1 (EMP1) on the steady-state mRNA level (by quantitative real-time PCR) and on the protein level (by western immunoblot and immunohistochemistry) in 51 pairs of laryngeal carcinoma tissues and matched cancer-free peritumor tissues， and we analyzed the correlation between EMP1 expression and different clinicopathological factors. Furthermore， we ectopically expressed EMP1 in human laryngeal carcinoma Hep-2 cells and examined the effects on cell viability， apoptosis， colonogenicity， and motility， by MTT assay， flow cytometry， colony formation assay and Transwell migration assay， respectively. EMP1 expression (on both the mRNA and protein levels) was significantly lower in the cancer tissues than in matched peritumor tissues (P<0.05). In laryngeal cancers， the level of EMP1 protein was correlated with histological grade (P<0.05)， but not with age， gender， clinical stage， cancer subtype or lymph node metastasis (P>0.05). Functionally， ectopic expression of EMP1 in Hep-2 cells significantly reduced cell viability， colony formation， and migration， but enhanced apoptosis. Therefore， EMP1 is a tumor suppressor in laryngeal carcinoma. Boosting EMP1 expression in laryngeal carcinoma initiates multiple anticancer phenotypes and thus presents a promising therapeutic strategy for laryngeal cancer.